|   LifeSciVC

Biotech Insider Stock Sales: Peer Benchmarks And Guidelines

By Bruce Booth, DPhil, Partner


Over the past six years, the biotech sector has experienced an incredible run of IPOs, reflecting the longest and largest “open window” for new offerings. Much has been written about post-IPO performance here and elsewhere, but there’s been little discussion about equity sales by executive teams following these IPOs.

Read more.